Incyte Shares Sold by Dodge & Cox

Institutional investor reduces stake in biopharmaceutical company

Mar. 14, 2026 at 8:09am

Got story updates? Submit your updates here. ›

Dodge & Cox, a major institutional investor, reduced its position in Incyte Corporation by 4.5% during the 3rd quarter, according to a recent SEC filing. The firm previously owned 13,932,416 shares, or about 7.10% of the biopharmaceutical company's stock, valued at $1.18 billion.

Why it matters

Incyte is a prominent biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases. Institutional investors closely monitor and adjust their positions in companies like Incyte, which can signal broader market trends and investor sentiment.

The details

Dodge & Cox sold 662,765 shares of Incyte stock during the 3rd quarter, reducing its total stake to 13,932,416 shares. The firm cited standard portfolio management practices as the reason for the sale. Other major institutional investors, including AustralianSuper Pty Ltd and Rakuten Investment Management Inc., also adjusted their Incyte positions during the quarter.

  • Dodge & Cox reduced its Incyte stake during the 3rd quarter of 2026.

The players

Dodge & Cox

A major institutional investor that previously owned 7.10% of Incyte Corporation's stock.

Incyte Corporation

A biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Dodge & Cox's Incyte position reflects standard portfolio management practices, but it also highlights the volatility and uncertainty surrounding the biopharmaceutical industry. Investors will continue to closely monitor Incyte's performance and developments in its drug pipeline.